EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Risk of Virological Failure After Switch to a Tenofovir‐Sparing Dual Therapy in Virologically Suppressed People With HIV and Past HBV Infection

A Borghetti, A Giacomelli, P F Salvo, A Cervo iD, S Colombaioni iD, F Lagi, G Baldin iD, C Mussini, L Oreni, S Antinori, G Formica, M Menozzi und 3 weitere

Journal of Medical Virology · 2026

DOI: 10.1002/jmv.71070 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Medical Virology, 2026. Verfasst von A Borghetti und 14 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Department, Azienda Ospedaliero-Universitaria Pisana, University of Pisa, Pisa, Italy. Hauptthemen laut MEDLINE: Tenofovir, HIV Infections, Anti-HIV Agents, Hepatitis B. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We compared the effectiveness of tenofovir (TFV)‐based triple regimens (TT) to TFV‐sparing dual therapies (DT) in virologically suppressed, HBsAg−/HBcAb+ people living with HIV (PLWH). We emulated a target trial including adults PLWH from five University Hospitals, with HBsAg−/HBcAb+ serostatus, starting a TT with unsuppressed serum HIV‐RNA and reaching HIV‐RNA < 50 cp/mL (baseline). PLWH starting a DT (3TC + bPI or DTG, DTG + RPV, DOR + DTG or long‐acting CAB + RPV) were considered in the “treatment”‐group only if they switched within a 1‐year grace period; all other PLWH were considered “control”‐group. To emulate randomization, participants were cloned at baseline and assigned the opposite strategy, then censored at the time of strategy‐deviation and assigned a weight based on the inverse‐probability of being uncensored. Probabilities of 5‐year virological failure (VF; two consecutive HIV‐RNA > 50 cp/mL or a single HIV‐RNA ≥ 200 cp/mL) were estimated through a weighted Kaplan–Meier estimator. Overall, 415 PLWH were eligible for study analysis: 71 (17.1%) started a DT (3TC‐based: 78.9%) during follow‐up. They were mainly men (329, 79.3%), with a median age of 48 years. In the weighted analysis, the estimated probabilities of VF were: 29.3% for DT and 29.9% for TT at 5 years (difference: 0.5%; 95% CI: −28.7, +21.6). A higher VF risk was seen in the subset of PLWH with undetectable HBsAb at the longest follow‐up available (4 years), independently of treatment group: 15.5% and 36.8% with DT and TT, respectively (difference: −21.3%; 95% CI: −30.3, −13.8). Switch to a TFV‐sparing DT, compared with continuing a TT, was not associated with an increased risk of VF in PLWH and prior HBV infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TenofovirHIV InfectionsAnti-HIV AgentsHepatitis BHumansMaleAdultTreatment FailureFemaleViral LoadMiddle AgedRNA, ViralCoinfectionAntiretroviral Therapy, Highly ActiveDrug Therapy, CombinationHepatitis B Surface Antigens

Stichwörter der Autor:innen

HBVHIVHIV‐HBV coinfectiondual therapyemulation trial

Substanzen

TenofovirAnti-HIV AgentsRNA, ViralHepatitis B Surface Antigens

Autor:innen und Institutionen

  • Infectious Diseases Department, Azienda Ospedaliero-Universitaria Pisana, University of Pisa, Pisa, Italy.
  • III Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy.
  • Infectious Diseases Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • Department of Infectious Diseases, Azienda Ospedaliero-Universitaria of Modena, Modena, Italy.
  • Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
  • Catholic University of the Sacred Heart, Rome, Italy.

ORCID-Profile: A Cervo, S Colombaioni, G Baldin, A Gori

Zitieren

APA

Borghetti, A., Giacomelli, A., Salvo, P. F., Cervo, A., Colombaioni, S., Lagi, F., Baldin, G., Mussini, C., Oreni, L., Antinori, S., Formica, G., Menozzi, M., Di Giambenedetto, S., Gori, A., & Falcone, M. (2026). Risk of Virological Failure After Switch to a Tenofovir‐Sparing Dual Therapy in Virologically Suppressed People With HIV and Past HBV Infection. Journal of Medical Virology. https://doi.org/10.1002/jmv.71070

Vancouver

Borghetti A, Giacomelli A, Salvo PF, Cervo A, Colombaioni S, Lagi F, et al. Risk of Virological Failure After Switch to a Tenofovir‐Sparing Dual Therapy in Virologically Suppressed People With HIV and Past HBV Infection. Journal of Medical Virology. 2026. doi:10.1002/jmv.71070

BibTeX
@article{Borghetti2026,
  author = {Borghetti, A and Giacomelli, A and Salvo, P F and Cervo, A and Colombaioni, S and Lagi, F and Baldin, G and Mussini, C and Oreni, L and Antinori, S and Formica, G and Menozzi, M and Di Giambenedetto, S and Gori, A and Falcone, M},
  title = {Risk of Virological Failure After Switch to a Tenofovir‐Sparing Dual Therapy in Virologically Suppressed People With HIV and Past HBV Infection},
  journal = {Journal of Medical Virology},
  year = {2026},
  doi = {10.1002/jmv.71070}
}
Kostenlos starten →